CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/79556

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/79556

Title:	CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells
Authors:	Ts, Hsiao-Chi;Tsai, Hsiao-Chi;Hua, Chun-Yin;Huang, Chun-Yin;Su, Hong-Lin;Su, Hong-Lin;湯智昕;Chih-Hsin, Tang
Contributors:	生物科技學系
Date:	2014-03
Issue Date:	2014-06-04 02:16:25 (UTC+0)
Abstract:	Osteosarcoma is the most common primary malignant tumor, and its treatments require more effective therapeutic approaches. Paclitaxel has a broad range of antitumor activities, including apoptosis-inducing effects. However, the majority of tumors in patients with advanced cancer eventually develop chemoresistance. Connective tissue growth factor (CTGF) is a secreted protein that modulates the invasiveness of certain human cancer cells by binding to integrins. However, the effect of CTGF in paclitaxel-mediated chemotherapy is unknown. Here, we report that the expression of CTGF in osteosarcoma patients was significantly higher than that of the CTGF expression in normal bone tissues. Overexpression of CTGF increased the resistance to paclitaxel-mediated cell apoptosis. In contrast, knockdown of CTGF expression by CTGF shRNA increased the chemotherapeutic effect of paclitaxel. In addition, CTGF increased resistance to paclitaxel-induced apoptosis through upregulation of survivin expression. Moreover, the AMP-activated protein kinase (AMPK)-dependent nuclear factor kappa B (NF-κB) pathway mediated paclitaxel-increased chemoresistance and survivin expression. In a mouse xenograft model, overexpression of CTGF promoted resistance to paclitaxel. In contrast, knockdown of CTGF expression increased the therapeutic effect of paclitaxel in this model. In conclusion, our data indicate that CTGF might be a critical oncogene of human osteosarcoma involved in resistance to paclitaxel treatment.
Relation:	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1843(5):846-854.
Appears in Collections:	[生物科技學系] 期刊論文

Files in This Item:

File	Size	Format
index.html	0Kb	HTML	382	View/Open

Loading...